
|Articles|September 1, 2003
Emerging Gold Standard?
San Francisco - More than two decades after collagen launched a revolution in filling facial wrinkles, the FDA is expected to approve the soft filler hyaluronic acid (Restylane, Q-Med) within the next few months. The approval will be partly based on a phase III study that showed it provides longer-lasting correction of nasolabial folds than collagen.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clinicians Weigh Topical Sequencing and Escalation in Complex Atopic Dermatitis Cases
2
Phase 3 STOP-HS Trials Highlight Promise of Oral JAK1 Inhibition for Moderate to Severe Disease
3
Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial
4
Common Mistakes in Managing Hair Loss and Pigmentary Disorders
5











